Rapid Urine Test Detects Early Kidney Injury
|
By LabMedica International staff writers Posted on 05 May 2014 |
|
Image: The NephroCheck Test cartridge and Astute140 Meter (Photo courtesy of Astute Medical).
A new test utilizes fluorescence immunoassay technology to detect and measure two biomarkers that reflect the risk of developing acute kidney injury (AKI).
The NephroCheck Test measures tissue inhibitor of metalloproteinase 2 (TIMP-2) and insulin-like growth factor binding protein 7(IGFBP-7) in human urine. Both are involved in G1 cell cycle arrest during the very early phases of cellular stress, and are robust measures of risk for AKI manifesting within the following 12-24 hours. TIMP-2 is an inhibitor of the matrix metalloproteinases (MMPs) that directly suppress the proliferation of endothelial cells. IGFBP-7 is involved in the regulation of tissue availability of insulin and IGFs, and stimulates cell adhesion implicated in epithelial cell-cycle arrest.
For the test, a sample of a patient’s urine is mixed with reagents onto a single-use cartridge inserted into the proprietary Astute140 Meter. The meter employs a sandwich immunoassay technique along with fluorescence detection technology to quantitatively measure the biomarker concentrations, combining them into a single numerical test result. Multiple levels of controls (internal, external, and electronic) are used to ensure reliable and accurate results in about 20 minutes. The NephroCheck Test and Astute140 Meter are products of Astute Medical (San Diego, CA, USA), and have received the European Community CE marking of approval.
“We believe the NephroCheck Test will be able to help physicians address one of the most costly, deadly, and confounding conditions affecting intensive care hospital patients,” said Chris Hibberd, CEO of Astute Medical. “With increasing constraints on healthcare spending, innovative tools such as the NephroCheck Test will be essential to ensuring that the right resources get to the right patients at the right time.”
AKI is a significant global health hazard that strikes up to seven percent of hospitalized patients. AKI often occurs in patients that are already suffering from myriad issues such as sepsis, trauma, surgery, or being treated with nephrotoxic drugs, further complicating diagnosis, while also increasing mortality rates.
Related Links:
Astute Medical
The NephroCheck Test measures tissue inhibitor of metalloproteinase 2 (TIMP-2) and insulin-like growth factor binding protein 7(IGFBP-7) in human urine. Both are involved in G1 cell cycle arrest during the very early phases of cellular stress, and are robust measures of risk for AKI manifesting within the following 12-24 hours. TIMP-2 is an inhibitor of the matrix metalloproteinases (MMPs) that directly suppress the proliferation of endothelial cells. IGFBP-7 is involved in the regulation of tissue availability of insulin and IGFs, and stimulates cell adhesion implicated in epithelial cell-cycle arrest.
For the test, a sample of a patient’s urine is mixed with reagents onto a single-use cartridge inserted into the proprietary Astute140 Meter. The meter employs a sandwich immunoassay technique along with fluorescence detection technology to quantitatively measure the biomarker concentrations, combining them into a single numerical test result. Multiple levels of controls (internal, external, and electronic) are used to ensure reliable and accurate results in about 20 minutes. The NephroCheck Test and Astute140 Meter are products of Astute Medical (San Diego, CA, USA), and have received the European Community CE marking of approval.
“We believe the NephroCheck Test will be able to help physicians address one of the most costly, deadly, and confounding conditions affecting intensive care hospital patients,” said Chris Hibberd, CEO of Astute Medical. “With increasing constraints on healthcare spending, innovative tools such as the NephroCheck Test will be essential to ensuring that the right resources get to the right patients at the right time.”
AKI is a significant global health hazard that strikes up to seven percent of hospitalized patients. AKI often occurs in patients that are already suffering from myriad issues such as sepsis, trauma, surgery, or being treated with nephrotoxic drugs, further complicating diagnosis, while also increasing mortality rates.
Related Links:
Astute Medical
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Electrolyte Analyzer
BKE-B
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Latest Clinical Chem. News
- Updated PSA Testing Guidelines Support Early Prostate Cancer Detection
- Antibody-Free Blood Test Detects Rheumatic Heart Disease Biomarker
- Blood and Spinal Fluid Biomarker May Help Track Early Huntington’s Disease
- New Biomarker Offers Longer Detection Window for Suspected GHB Exposure
- Study Finds Urine Biomarker Score Improves Five-Year Cancer Risk Prediction
- Flow Cytometry Tests Receive FDA Clearance for B-Cell Lymphoma Diagnosis
- Blood Protein Signatures May Predict Brain Vessel Damage and Cognitive Decline
- Combined Blood and Imaging Data Help Identify More Lung Cancer Cases
- Blood Protein Panel Detects ALS with High Accuracy
- Single-Vesicle Analysis Reveals Tissue-Associated Inflammatory Signatures
- Plasma Proteomic Test Detects Immunotherapy Resistance Before Imaging in Lung Cancer
- Blood Protein Analysis Reveals Menopause-Associated Signals of Brain Aging
- Noninvasive Tests Offer Alternatives to Biopsy for Assessing Advanced Liver Scarring
- Blood-Based Score May Support Targeted Interventions for Healthier Aging
- Cystatin C Testing Helps Distinguish Abemaciclib Effect from Kidney Injury
- Blood Proteins Linked to Mortality Risk and Biological Aging Across Organ Systems
Channels
Molecular Diagnostics
view channel
AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026
Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more
AMP 2026 Highlights Advances in Molecular Testing for Pediatric Diseases
Advances in molecular diagnostics are creating new opportunities to identify inherited diseases earlier, improve the classification of childhood cancers, and track infectious disease outbreaks affecting children.... Read more
Genomic Studies Investigate Treatment Response and Inherited Risk in Sarcoma
Tempus AI (Chicago, IL, USA) will present six abstracts, including three oral presentations, at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting, taking place November 18–21 in Seoul, South Korea.... Read more
Hematology
view channel
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read more
Study Confirms Blood Products Remain Viable After Three Weeks in the Arctic
Trauma and hemorrhage care in Canada’s High Arctic is complicated by long evacuation times, extreme temperatures, and limited access to blood products. In remote military and northern communities, reaching... Read more
Immunology
view channel
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read more
Microbiology
view channel
Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum
Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more
Automated Microbial Identification and Susceptibility System Gains FDA Clearance
Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more
Gastrointestinal Flex Assay Gains EU Certification for Tailored Pathogen Testing
Gastrointestinal infections can be caused by bacterial, viral, or parasitic pathogens, making targeted test selection important for clinical laboratories. Fixed syndromic panels may be broader than necessary... Read more
Molecular Panels Gain FDA Clearance for One-Hour Gastrointestinal Pathogen Testing
Acute infectious gastroenteritis, caused by viral, bacterial, and parasitic pathogens, remains a significant global health concern that inflames the gastrointestinal tract. Symptoms such as diarrhea, vomiting,... Read morePathology
view channel
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more
Breakthrough-Designated Cytology Test Supports Oral Cancer Risk Assessment
Oral cavity and oropharyngeal cancers remain a significant diagnostic challenge, with more than 60,000 Americans expected to be diagnosed in 2026 and more than 13,000 expected to die from these cancers.... Read more
AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read more
Industry
view channel
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more
